1262108-14-4

Basic information

• Product Name: Vistusertib
• Synonyms: Vistusertib
• CAS NO: 1262108-14-4
• Molecular Formula: C₂₇H₂₉F₅O₄S
• Molecular Weight: 544.573776
• Mol File: 1262108-14-4.mol

Chemical Properties

• Boiling Point: 651.1±55.0 °C(Predicted)
• Appearance: /
• Density: 1.41±0.1 g/cm3(Predicted)
• PKA: 12.13±0.60(Predicted)
• CAS DataBase Reference: Vistusertib(CAS DataBase Reference)
• NIST Chemistry Reference: Vistusertib(1262108-14-4)
• EPA Substance Registry System: Vistusertib(1262108-14-4)

Safety Data

• Hazardous Substances Data: 1262108-14-4(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
Vistusertib is used as an anticancer agent for its potential to treat various types of cancer. It targets the mTOR protein, which is involved in cell growth and proliferation, thereby disrupting the signaling pathways that contribute to cancer development and progression.
Used in Combination Therapy:
Vistusertib is used in combination with other anticancer drugs to enhance the efficacy of cancer treatment. Clinical trials have shown that its dual inhibition of mTORC1 and mTORC2 can improve the effectiveness of existing therapies and potentially overcome resistance to conventional treatments.
Used in Targeted Cancer Therapy Research:
Vistusertib is utilized in ongoing research to evaluate its potential as a targeted therapy for a range of cancer types. Its dual mTORC1 and mTORC2 inhibitory action is being explored for its ability to provide more precise and effective treatments for cancer patients, with the goal of minimizing side effects and improving patient outcomes.

Upstream product

• 1262108-06-4 (11β,17β)-20,20,21,21,21-pentafluoro-17-hydroxy-11-[4-(methylsulfanyl)phenyl]-19-norpregna-4,9-dien-3-one 
• 1262108-37-1 (5R,8S,11R,13S,14S,17S)-5',5',13-trimethyl-11-[4-(methylsulfanyl)phenyl]-17-(pentafluoroethyl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxane]-5,17(4H)-diol 
• 1026668-61-0 (5′R,8′S,10′R,13′S,14′S,17′S)-5,5,13′-trimethyl-17′-(pentafluoroethyl)-1′,2′,7′,8′,12′,13′,14′,15′,16′,17′-decahydro-6′H-spiro[1,3-dioxane-2,3′-[5,10]epoxycyclopenta[a]phenanthren]-17′-ol 
• 91175-93-8 (5′R,8′S,10′R,13′S,14′S)-5,5,13′-trimethyl-1′,2′,6′,7′,8′,12′,13′,14′,15′,16′-decahydro-17′H-spiro[1,3-dioxane-2,3′-[5,10]epoxycyclopenta[a]phenanthren]-17′-one 

Relevant articles and documents

SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRM) AND STABILIZED ESTROGEN LEVEL IN PATIENT

The present invention is related to Selective Progesterone Receptor Modulators (SPRM) as described and defined herein, and covers the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of sexual hormone de

Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies

Progesterone plays an important role in the female reproductive system. However, there is also evidence that gynecologic disorders/diseases such as uterine fibroids and endometriosis are progesterone-dependent. Steroidal and non-steroidal selective progesterone receptor modulators (SPRMs) have shown potential for the treatment of such diseases. Steroidal SPRMs, including mifepristone and ulipristal acetate, have proven effective in clinical trials. However, several steroidal SPRMs containing a dimethylamino substituent have been associated with elevated liver enzymes in patients. An earlier drug discovery program identified lonaprisan as a highly selective SPRM that did not show drug-related change in liver enzyme activity. Building on data obtained from that work, here we describe the research program that culminated in the discovery of a novel steroidal SPRM, vilaprisan, which combines an extremely high potency with very favorable drug metabolism and pharmacokinetic properties. Vilaprisan has entered clinical development and is currently undergoing phase 3 clinical trials.

17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES

The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereo